Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis

Leukemia

Volumn 17, Issue 9, 2003, Pages 1806-1812

  Liesveld, J L ^a   Lancet, J E ^a   Rosell, K E ^a   Menon, A ^a   Lu, C ^a   McNair II, C ^a   Abboud, C N ^a   Rosenbatt, J D ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Farnesyl transferase inhibitors; Hematopoiesis; Myelodysplasia

Indexed keywords

CD34 ANTIGEN; LIPID; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW SUPPRESSION; CANCER INHIBITION; CELL ADHESION; CELL CULTURE; CELL CYCLE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELODYSPLASIA; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION;

EID: 0141502201     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403063     Document Type: Article

References (23)

1. Khosvari-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to ras function and cancer intervention. Cell Growth Diff 1992; 3: 461-469.
2. End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs 1999; 17: 241-258.
3. Bearupe DM, Kurzrock RA. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999; 17: 1071-1079.
4. Cox AD, Der CJ. Farnesyl inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1997; 1333: F51-F71.
5. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM et al. The phosphoinositide 3-OH-kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139-148.
6. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angiboud P et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-137.
7. Rowinsky EK, Windle JJ, Van Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631-3652.
8. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369.
9. Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge D. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991; 78: 666-672.
10. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000; 28: 660-671.
11. Liesveld JL, Frediani KE, Harbol AW, DiPersio JF, Abboud CN. Characterization of the adherence of normal and leukemic CD34+ cells to endothelial monolayers. Leukemia 1994; 12: 211-217.
12. Liesveld JL, Rosell K, Panoskaltsis N, Belanger T, Harbol A, Abboud CN. Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activation. J Hematother Stem Cell Res 2001; 10: 643-655.
13. Reykdal S, Abboud C, Liesveld JL. Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. Exp Hematol 1999; 27: 441-450.
14. Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem 2002; 2: 303-323.
15. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics E acute myelogenous leukemia progenitors that initiate malignant hernatopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761-1772.
16. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18: 927-941.
17. Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001; 12: 193-197.
18. Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 1997; 57: 708-713.
19. Epp-Lorenzion L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-5309.
20. Gouill SL, Pellat-Deceunynck C, Harousseau J-L, Rapp J-J, Robillard N, Bataille R et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002; 16: 164-167.
21. Du W, Liu A, Prendergast GC. Activation of the IGF-PI3′K pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999; 59: 4208-4212.
22. Prendergast G. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 2000; 12: 166-173.
23. Moasser MM, Sepp-Lorenzion L, Kohl NE, Oliff A, Balog A, Su DS et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369-1374.